Kexing signs 6 national major scientific and technological projects again.

Recently, Beijing Kexing Zhongwei Biotechnology Co., Ltd., a subsidiary of the Kexing Group, officially signed 6 "Newly Emerging Infectious Diseases and Major Infectious Disease Prevention and Control" national key research and development project contracts, covering the research and development of various pathogens related to vaccines and antibody drugs such as Ebola virus, Marburg virus, Dengue virus, Zika virus, as well as the mechanism of severe conversion of important mosquito-borne viral diseases and early intervention plans. The "Newly Emerging Infectious Diseases and Major Infectious Disease Prevention and Control" national key research and development project aims to target the major strategic needs of the country in the field of infectious disease prevention and control, and systematically layout the key technologies for vaccine, drug, and prevention and control research.